臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

About TAIR
	About TAIR

Browse By
	Institution
	Author
	Title
	Date
	Statistics Chart
	Institution Facts
	Trend

News
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

Copyright
	Publisher & Journal Policy
	TAIR Copyright Conference Minutes

Related Links
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

Jump to a point in the index:
Or type in a year:

Show Most Recent First

Ordering With Oldest First

Showing items 2261116-2261140 of 2349128 (93966 Page(s) Totally)
<< < 90440 90441 90442 90443 90444 90445 90446 90447 90448 90449 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2022-02-21T02:04:35Z	Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study	Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG
臺大學術典藏	2022-02-21T02:04:35Z	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT	Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H.
臺大學術典藏	2022-02-21T02:04:35Z	Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial	Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y.
臺大學術典藏	2022-02-21T02:04:36Z	Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages	Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG; Yang M.-H.; Hsu C.
臺大學術典藏	2022-02-21T02:04:36Z	Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy	Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2022-02-21T02:51:54Z	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study	Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J.
臺大學術典藏	2022-02-21T02:51:54Z	Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy	YING-CHUN SHEN; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L.
臺大學術典藏	2022-02-21T02:51:55Z	Evolution of systemic treatment for advanced hepatocellular carcinoma	Wu T.-C.; YING-CHUN SHEN; Cheng A.-L.
臺大學術典藏	2022-02-21T03:52:30Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC	Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏	2022-02-21T03:52:31Z	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours	de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L.
臺大學術典藏	2022-02-21T03:52:31Z	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib	Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2022-02-21T03:52:32Z	A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors	JIH-HSIANG LEE; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C.
臺大學術典藏	2022-02-21T03:52:32Z	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors	Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2022-02-21T03:52:33Z	Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors	JIH-HSIANG LEE; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; Shih J.-Y.; Yu C.-J.; Chen K.-Y.; Tsai T.-H.; Yang J.C.-H.
臺大學術典藏	2022-02-21T03:52:33Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; JIH-HSIANG LEE; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2022-02-21T03:52:34Z	Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients	Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H.
臺大學術典藏	2022-02-21T03:52:34Z	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors	Liao B.-C.; Bai Y.-Y.; JIH-HSIANG LEE; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C.
臺大學術典藏	2022-02-21T03:52:35Z	Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study	Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.
臺大學術典藏	2022-02-21T03:52:35Z	Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan	Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J.
臺大學術典藏	2022-02-21T03:52:36Z	Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy	Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H.
臺大學術典藏	2022-02-21T03:52:36Z	Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors	Chang I.-S.; Jiang S.S.; Yang J.C.-H.; Su W.-C.; Chien L.-H.; Hsiao C.-F.; JIH-HSIANG LEE; Chen C.-Y.; Chen C.-H.; Chang G.-C.; Wang Z.; Lo F.-Y.; Chen K.-Y.; Wang W.-C.; Chen Y.-M.; Huang M.-S.; Tsai Y.-H.; Su Y.-C.; Hsieh W.-S.; Shih W.-C.; Shieh S.-H.; Yang T.-Y.; Lan Q.; Rothman N.; Chen C.-J.; Chanock S.J.; Yang P.-C.; Hsiung C.A.
臺大學術典藏	2022-02-21T03:52:36Z	New data on clinical decisions in NSCLC patients with uncommon EGFR mutations	Wu T.; Hsiue E.H.; JIH-HSIANG LEE; Lin C.; Yang J.C.
臺大學術典藏	2022-02-21T03:52:37Z	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer	Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T.
臺大學術典藏	2022-02-21T03:52:37Z	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors	Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H.
臺大學術典藏	2022-02-21T03:52:37Z	Profile of the therascreen? EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer	Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H.

Showing items 2261116-2261140 of 2349128 (93966 Page(s) Totally)
<< < 90440 90441 90442 90443 90444 90445 90446 90447 90448 90449 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| Total items :0
	Visitors : 53182743 Online Users : 629 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library